Be­lieve it or not: an in­stant ‘ba­bal­aas’ rem­edy

CityPress - - News - ZINHLE MAPUMULO zinhle.mapumulo@city­

Imag­ine a sci­en­tif­i­cally proven cure for a hang­over that works in an in­stant. Sounds lu­di­crous, right? But South Africans will soon get a chance to test this “cure” if all goes well with the lat­est clin­i­cal tri­als.

It’s called Ab­sorba­tox and is in the fi­nal stages of test­ing af­ter eight years of rig­or­ous tri­als.

Pro­duced by lo­cal phar­ma­ceu­ti­cal com­pany Gast Lab­o­ra­to­ries, Ab­sorba­tox claims to con­tain mod­i­fied nat­u­ral min­er­als and prom­ises to clear your gas­troin­testi­nal tract and get rid of symp­toms re­lated to veisal­gia, com­monly known as ba­bal­aas.

Dr Jac­ques Sny­man of Gast Lab­o­ra­to­ries de­scribed how it works: “Imag­ine you have tox­ins or other ad­verse cells in your body – with this dis­cov­ery we can ‘pro­gramme’ the nat­u­ral min­eral to go and fetch th­ese tox­ins, and re­place them with cal­cium or mag­ne­sium, for in­stance. It acts like a pro­gram­mable mop that can do what it is told or de­signed to do,” he said.

Ab­sorba­tox, which can be ad­min­is­tered orally or top­i­cally, is in its fi­nal stages of de­vel­op­ment and has al­ready shown sig­nif­i­cant promis­ing re­sults.

In a study pub­lished in the on­line Dove Med­i­cal Press jour­nal in Jan­uary, the sub­stance showed that it sig­nif­i­cantly re­duced symp­toms as­so­ci­ated with ba­bal­aas in the cen­tral ner­vous sys­tem and gas­troin­testi­nal tract.

Ba­bal­aas symp­toms in­clude headache, nau­sea, vom­it­ing, ir­ri­ta­tion, tremor, thirst and a dry mouth.

The ma­jor prob­lem with ex­pos­ing the gas­troin­testi­nal tract to al­co­hol is the lo­cal or cy­to­toxic ef­fects on the cells of the gut lin­ing, which re­sults in the re­lease of free rad­i­cals, as well as, in some peo­ple, the re­lease of me­di­a­tors, which may re­sult in headaches, nau­sea and other typ­i­cal symp­toms of veisal­gia.

But Ab­sorba­tox prom­ises to re­duce the ab­sorp­tion of th­ese me­di­a­tors and, by so do­ing, re­duce their ef­fects sys­tem­i­cally.

Sny­man said that ob­vi­ously this tech­nol­ogy had some dis­tance to go be­fore sub­stan­tial com­mer­cial re­sults would be seen.

“This nat­u­ral tech­nol­ogy has to date shown zero side ef­fects be­cause it is an in­gested item that is ex­creted again. It has sig­nif­i­cant po­ten­tial to rev­o­lu­tionise our un­der­stand­ing of the gas­troin­testi­nal phys­i­ol­ogy and how it con­trib­utes to health and dis­ease [con­trol],” he said.

Dr Kevin Gast, group chair at Gast Lab­o­ra­to­ries, could not con­tain his ex­cite­ment about the com­pany’s de­vel­op­ment.

“We are be­yond ex­cited by this new dis­cov­ery; our team at Gast Lab­o­ra­to­ries has spent many hours do­ing in-depth re­search to get to this point.

“Ob­vi­ously, hav­ing in­vested heav­ily in this tech­nol­ogy’s de­vel­op­ment, we are ea­ger to see its com­mer­cial value and, most im­por­tantly, the ben­e­fits it can bring to mod­ern sci­ence and the treat­ment of pa­tients,” he said.

Newspapers in English

Newspapers from South Africa

© PressReader. All rights reserved.